Clinical Trials in Cleveland

Showing 5921-5940 of 19,775 trials

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

NCT01997840

Phase 1b: To evaluate the side effects and determine the best dose of ACY-1215 in combination with Pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma. Phase 2: To determine the overall response rate of ACY-1215 in combination with Pomolidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma

Multiple Myeloma

Celgene103 participantsStarted Mar 2014

Boston, Massachusetts, United States • Cleveland, Ohio, United States

TERMINATEDPhase 2< 1 mile

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

NCT04840199

This was an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who were on antiretroviral therapy (ART)-mediated suppression. Participants were randomly assigned to receive either letermovir once daily or no anti-CMV treatment, for 48 weeks. The primary hypothesis of this study was that letermovir would cause a greater reduction in plasma soluble receptor for tumor necrosis factor type II (sTNFRII) levels than no anti-CMV treatment at weeks 46/48.

HIV InfectionsCytomegalovirusCMV

National Institute of Allergy and Infectious Diseases (NIAID)44 participantsStarted Apr 2022

San Diego, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +12 more locations

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

Find Trials by Condition in Cleveland

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Lipoic Acid for Progressive Multiple Sclerosis (MS)

Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder

ViBone in Cervical and Lumbar Spine Fusion

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

Cardiovascular Risk Screening and Risk Reduction in Women Vets

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer